FIGURE

Fig. 3

ID

ZDB-FIG-250521-37

Publication

Þorsteinsson et al., 2025 - Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records

Other Figures

All Figure Page

Back to All Figure Page

Fig. 3

c-Fos expression in adgrl3.1^−/− zebrafish in the telencephalon following amlodipine exposure.

A schematic representation of a 6 dpf zebrafish larva, red dashed rectangle within the telencephalon denotes the area used for counting. Representative figures of immunohistochemically labeled c-Fos of adgrl3.1^−/− zebrafish larvae treated with (B) 10 µM amlodipine and (C) 0.1% DMSO and WT zebrafish larvae treated with (D) 10 µM amlodipine and (E) 0.1% DMSO. F c-Fos count for each group. Data are depicted as mean ± SEM, n = 20, one-way ANOVA followed by Tukey’s multiple comparisons test, *P ≤ 0.05, **P ≤ 0.01, (scale bar = 10 µm). G levels of amlodipine in brain and plasma following 1 or 10 mg/kg oral dose after single or 5-day doses in rats.

Expression Data

Antibody:	Ab3-fosab
Fish:	WT adgrl3.1^{zf3892/zf3892}
Condition:	chemical treatment by environment: amlodipine
Anatomical Term:	telencephalon
Stage:	Day 6

Expression Detail

Antibody Labeling

Phenotype Data

Fish:	WT adgrl3.1^{zf3892/zf3892}
Condition:	chemical treatment by environment: amlodipine
Observed In:	telencephalon
Stage:	Day 6

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Neuropsychopharmacology